In particular, our data demonstrate the advantages of dual-drug ADCs for treating low-HER2 breast tumors over co-administration of two single-drug ADCs carrying the same payloads, which one may think would be as effective as the former approach. Here, ERBB2 is linked to breast neoplasm.